Among the described factors contributing to plasma cell persistence, the B cell maturation antigen (BCMA) encoded by the tumor necrosis factor receptor superfamily member 17 gene (Tnfrsf17) takes center stage as a proposed mediator of APRIL-dependent plasma cell survival (7) and a promising therapeutic target to treat plasma cell disorders including refractory multiple myeloma (8). Here, TNFRSF17 is linked to plasma cell neoplasm.